Cargando…

Amyloid Beta in Aging and Alzheimer’s Disease

Alzheimer’s disease (AD), is a progressive neurodegenerative disease that affects behavior, thinking, learning, and memory in elderly individuals. AD occurs in two forms, early onset familial and late-onset sporadic; genetic mutations in PS1, PS2, and APP genes cause early onset familial AD, and a c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sehar, Ujala, Rawat, Priyanka, Reddy, Arubala P., Kopel, Jonathan, Reddy, P. Hemachandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655207/
https://www.ncbi.nlm.nih.gov/pubmed/36361714
http://dx.doi.org/10.3390/ijms232112924
_version_ 1784829128685387776
author Sehar, Ujala
Rawat, Priyanka
Reddy, Arubala P.
Kopel, Jonathan
Reddy, P. Hemachandra
author_facet Sehar, Ujala
Rawat, Priyanka
Reddy, Arubala P.
Kopel, Jonathan
Reddy, P. Hemachandra
author_sort Sehar, Ujala
collection PubMed
description Alzheimer’s disease (AD), is a progressive neurodegenerative disease that affects behavior, thinking, learning, and memory in elderly individuals. AD occurs in two forms, early onset familial and late-onset sporadic; genetic mutations in PS1, PS2, and APP genes cause early onset familial AD, and a combination of lifestyle, environment and genetic factors causes the late-onset sporadic form of the disease. However, accelerated disease progression is noticed in patients with familial AD. Disease-causing pathological changes are synaptic damage, and mitochondrial structural and functional changes, in addition to increased production and accumulation of phosphorylated tau (p-tau), and amyloid beta (Aβ) in the affected brain regions in AD patients. Aβ is a peptide derived from amyloid precursor protein (APP) by proteolytic cleavage of beta and gamma secretases. APP is a glycoprotein that plays a significant role in maintaining neuronal homeostasis like signaling, neuronal development, and intracellular transport. Aβ is reported to have both protective and toxic effects in neurons. The purpose of our article is to summarize recent developments of Aβ and its association with synapses, mitochondria, microglia, astrocytes, and its interaction with p-tau. Our article also covers the therapeutic strategies that reduce Aβ toxicities in disease progression and discusses the reasons for the failures of Aβ therapeutics.
format Online
Article
Text
id pubmed-9655207
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96552072022-11-15 Amyloid Beta in Aging and Alzheimer’s Disease Sehar, Ujala Rawat, Priyanka Reddy, Arubala P. Kopel, Jonathan Reddy, P. Hemachandra Int J Mol Sci Review Alzheimer’s disease (AD), is a progressive neurodegenerative disease that affects behavior, thinking, learning, and memory in elderly individuals. AD occurs in two forms, early onset familial and late-onset sporadic; genetic mutations in PS1, PS2, and APP genes cause early onset familial AD, and a combination of lifestyle, environment and genetic factors causes the late-onset sporadic form of the disease. However, accelerated disease progression is noticed in patients with familial AD. Disease-causing pathological changes are synaptic damage, and mitochondrial structural and functional changes, in addition to increased production and accumulation of phosphorylated tau (p-tau), and amyloid beta (Aβ) in the affected brain regions in AD patients. Aβ is a peptide derived from amyloid precursor protein (APP) by proteolytic cleavage of beta and gamma secretases. APP is a glycoprotein that plays a significant role in maintaining neuronal homeostasis like signaling, neuronal development, and intracellular transport. Aβ is reported to have both protective and toxic effects in neurons. The purpose of our article is to summarize recent developments of Aβ and its association with synapses, mitochondria, microglia, astrocytes, and its interaction with p-tau. Our article also covers the therapeutic strategies that reduce Aβ toxicities in disease progression and discusses the reasons for the failures of Aβ therapeutics. MDPI 2022-10-26 /pmc/articles/PMC9655207/ /pubmed/36361714 http://dx.doi.org/10.3390/ijms232112924 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sehar, Ujala
Rawat, Priyanka
Reddy, Arubala P.
Kopel, Jonathan
Reddy, P. Hemachandra
Amyloid Beta in Aging and Alzheimer’s Disease
title Amyloid Beta in Aging and Alzheimer’s Disease
title_full Amyloid Beta in Aging and Alzheimer’s Disease
title_fullStr Amyloid Beta in Aging and Alzheimer’s Disease
title_full_unstemmed Amyloid Beta in Aging and Alzheimer’s Disease
title_short Amyloid Beta in Aging and Alzheimer’s Disease
title_sort amyloid beta in aging and alzheimer’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655207/
https://www.ncbi.nlm.nih.gov/pubmed/36361714
http://dx.doi.org/10.3390/ijms232112924
work_keys_str_mv AT seharujala amyloidbetainagingandalzheimersdisease
AT rawatpriyanka amyloidbetainagingandalzheimersdisease
AT reddyarubalap amyloidbetainagingandalzheimersdisease
AT kopeljonathan amyloidbetainagingandalzheimersdisease
AT reddyphemachandra amyloidbetainagingandalzheimersdisease